A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease.

Area of Science:

• Oncology
• Dermatology
• Immunology

Background:

• Significant advancements in melanoma treatment have emerged with immune checkpoint inhibitors and MAP kinase pathway inhibitors.
• These therapies have transformed the management of advanced and metastatic melanoma.

Approach:

• A comprehensive review of the clinical literature on first-line therapies for melanoma.
• Incorporation of current practice patterns from leading melanoma groups.

Key Points:

• First-line treatment strategies for melanoma are evolving rapidly.
• Immune checkpoint inhibitors and MAP kinase inhibitors represent key therapeutic classes.
• Areas of clinical uncertainty offer avenues for future research and improved patient outcomes.

Conclusions:

• The first-line setting for melanoma management is increasingly defined by targeted therapies.
• Further clinical investigation is crucial to optimize treatment strategies and enhance patient survival.
• Understanding practice patterns alongside literature review provides a holistic view of current melanoma care.